查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1725864

速效型胰岛素的全球市场，市场规模和占有率的分析 - 成长趋势与预测(2025年～2033年)

Rapid Acting Insulin Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

速效胰岛素市场趋势及总结

2024年，全球速效胰岛素市场规模为77.1亿美元，预计2033年将快速成长至117.7亿美元，2025年至2033年的复合年增长率为4.81%。

速效胰岛素市场成长动力

全球糖尿病盛行率上升

全球糖尿病负担（尤其是第1型和第2型糖尿病）不断加重是速效胰岛素市场的主要驱动力。根据国际糖尿病联盟的数据，2023年全球超过5.3亿成年人患有糖尿病，预计这一数字还将稳定成长。糖尿病患者数量的增长直接源于对有效的速效胰岛素治疗的需求增加，这种治疗用于控制餐后血糖。随着越来越多的患者需要精准的胰岛素剂量，医疗保健专业人员正在将速效胰岛素作为个人化治疗计画的一部分。各国政府和医疗体係也不断提高对糖尿病的认识，并加大对治疗设施的投资，这进一步推动了市场的成长。最近的预测显示，全球超过5.37亿成年人患有糖尿病，预计2045年这一数字将达到7亿。

胰岛素给药装置的进步

胰岛素笔、胰岛素帮浦和持续血糖监测系统的技术进步大大提高了速效胰岛素的便利性和有效性。目前的给药装置为患者提供了精准便捷的给药方式，降低了低血糖风险，并最大限度地控制了血糖。这些发展使得年轻且技术先进的患者扩大采用速效胰岛素製剂，也提高了治疗顺从性。与糖尿病管理应用程式和智慧胰岛素笔的兼容性也提高了这些胰岛素製剂的普及度。随着越来越多的医疗器材和製药公司参与合作，这些技术正在简化治疗，减少给药错误，改善患者的生活质量，并支持市场成长。 2024年8月，雅培与美敦力合作开发了基于雅培FreeStyle Libre技术的整合式连续血糖监测 (CGM) 系统。该系统将与美敦力的自动胰岛素输送系统和智慧胰岛素笔系统结合，自动调整胰岛素剂量。 CGM感测器将由雅培设计，并由美敦力销售。

转向个人化强化胰岛素治疗

糖尿病治疗中对精准医疗的需求日益增长，这增加了速效胰岛素在个人化治疗方案中的重要性。医生现在对能够密切反映生理性胰岛素分泌的强化胰岛素治疗很感兴趣，尤其是对于使用胰岛素的第一型糖尿病患者和第2型糖尿病患者。速效胰岛素是这项策略的关键组成部分，能够调节餐后血糖升高。此外，人们越来越意识到更严格的血糖控制对患者的益处，包括降低长期併发症的风险。以患者为中心的治疗方法以及越来越多地使用动态血糖监测 (CGM) 数据来指导胰岛素给药，正在推动全球对速效胰岛素的需求。 2024 年 11 月，InsuJet 无针设备将采用创新的喷射注射技术，无需针头即可精准注射胰岛素。它还能减轻针头注射带来的不适和焦虑。

速效胰岛素市场的障碍

速效胰岛素成本高

速效胰岛素市场的主要障碍之一是成本高昂，尤其是在医疗保险覆盖率较低的国家。赖脯胰岛素和门冬胰岛素的价格通常高于人类胰岛素，这使得中低收入国家的患者无法获得它们。即使在美国这样的已开发市场，胰岛素的供应仍然是一个主要问题，引发了社会压力和政策行动。生物相似药正逐渐进入市场以解决价格问题，但监管障碍和品牌影响力仍然是阻碍因素。过高的价格通常会导致胰岛素配给不足、依从性差以及不良的健康后果，从而损害服务欠缺地区的市场前景。

本报告提供全球速效型胰岛素市场相关调查，成长推动因素与课题，各市场区隔的分析，主要企业的分析等资讯。

目录

第1章 简介

第2章 调查和调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题
  • 机会

第5章 全球速效型胰岛素市场

第6章 市场占有率分析

  • 各产品
  • 各适应症
  • 各流通管道
  • 各国

第7章 产品

  • Lispro胰岛素
  • Aspart胰岛素
  • Glulisine胰岛素

第8章 适应症

  • 第一型糖尿病
  • 第二型糖尿病

第9章 流通管道

  • 医院药局
  • 药妆店，药局
  • 网路商店

第10章 国家

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 纽西兰
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东·非洲
    • 南非
    • 沙乌地阿拉伯
    • 土耳其
    • 阿拉伯联合大公国

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企业的分析

  • Adocia
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co. Ltd.
  • Geropharm
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhardt Ltd.
简介目录

Rapid Acting Insulin Market Trends & Summary

The Rapid Acting Insulin Market valued at USD 7.71 billion in 2024 is anticipated to grow strongly to USD 11.77 billion by 2033. This growth represents a strong compound annual growth rate (CAGR) of 4.81% from 2025 to 2033."

The report Rapid Acting Insulin Market Forecast covers by Product (Lispro Insulin, Aspart Insulin, Glulisine Insulin), Indication (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), Country and Company Analysis 2025-2033.

The growth is supported by growing diabetes prevalence, the need for proper glycemic control, and improved insulin delivery technologies.

Rapid Acting Insulin Market Outlooks

Rapid acting insulin, or fast-acting insulin, starts to act between 10 to 30 minutes after injection, peaks within 1 to 3 hours, and lasts for as long as 5 hours. It is mostly utilized to control postprandial blood glucose surges in people with diabetes, primarily Type 1 and complicated Type 2 diabetes. Examples include insulin lispro, insulin aspart, and insulin glulisine.

These insulins are commonly used in combination with long-acting insulins in a basal-bolus regimen to more closely approximate the body's own insulin secretion. Their rapid onset makes them particularly suitable for flexible meal scheduling and improved postprandial glucose control. Globally, rapid-acting insulin is increasingly popular because of the growing number of diabetes cases, rising use of insulin pens and pumps, and increased awareness of early and effective diabetes care. Advancements in biosimilars and affordability programs are also improving worldwide access.

Growth Drivers for the Rapid Acting Insulin Market

Increasing Global Prevalence of Diabetes

The rising global diabetes burden, particularly Type 1 and Type 2, is a key driver for the rapid acting insulin market. As per the International Diabetes Federation, more than 530 million adults lived with diabetes in 2023, and the number is expected to increase consistently. This increase in diabetic patient populations is directly attributed to increasing demand for effective, fast-acting insulin treatments to manage postprandial blood glucose. As more patients need accurate insulin dosing, healthcare professionals are prescribing rapid acting insulin as part of personalized treatment plans. Governments and healthcare systems are also investing more in diabetes awareness and treatment facilities, further propelling market growth. As of recent projections, more than 537 million adults have diabetes worldwide, and this number is estimated to reach 700 million by 2045.

Advances in Insulin Delivery Devices

Technological advancements in insulin pens, pumps, and continuous glucose monitoring systems have greatly improved the convenience and effectiveness of rapid acting insulin. Current delivery devices offer patients precise, easy dosing, lowering the risk of hypoglycemia and maximizing glycemic control. These developments have aided increased uptake of rapid acting insulins by younger and more technologically advanced patients, along with better adherence to treatment. Compatibility with diabetes management apps and smart insulin pens also enhances the popularity of these insulins. With more device and pharmaceutical companies coming together, these technologies are simplifying therapy, decreasing administration errors, and improving the quality of life for patients, thereby supporting market growth. Aug 2024, Abbott and Medtronic have partnered to create an integrated continuous glucose monitoring (CGM) system based on Abbott's FreeStyle Libre technology. The system will be combined with Medtronic's automated insulin delivery and smart insulin pen systems to automatically adjust insulin doses. Abbott will design the CGM sensor and Medtronic will sell it.

Shift Toward Personalized and Intensive Insulin Therapy

The growing need for precision medicine in the management of diabetes has raised the level of importance for rapid acting insulin in individualized treatment regimens. Physicians are now concerned with intensive insulin therapy that reflects physiological insulin release closely, specifically for Type 1 diabetics and Type 2 diabetic patients who use insulin. Rapid acting insulin is a pivotal component of the strategy, regulating blood sugar excursions following food intake. In addition, awareness of patient benefits for tighter glycemic control, such as reduced risks of long-term complications, is growing. Coupled with patient-focused treatment approaches and increased application of CGM data to direct insulin dosing, demand for rapid acting insulin is being driven globally. Nov 2024, The InsuJet Needle-free Device harnesses innovative jet injection technology to administer accurate insulin doses without the use of needles. It reduces discomfort and anxiety concerning needle injections.

Drawbacks of the Rapid Acting Insulin Market

High Cost of Rapid Acting Insulin

One of the major drawbacks in the market of rapid acting insulin is that it is too costly, especially in nations lacking widespread healthcare coverage. Insulin lispro and insulin aspart are usually priced above human insulin, making them unavailable to low- and middle-income countries' patients. Even in developed markets such as the U.S., the affordability of insulin remains a significant issue that triggers public pressure as well as policy action. Although biosimilars are gradually coming into the market to fix the problem of price, regulatory obstacles and brand strength continue to be limiting factors. Exorbitant prices usually result in high rates of insulin rationing, lowered compliance, and undesirable health consequences, defiling market potential in underserved areas.

Regulated and Cold Chain Requirements

Manufacture, approval, and distribution of rapid acting insulin demand compliance with strict regulatory controls and temperature-controlled supply. Sustaining the cold chain during the supply chain is essential to ensuring insulin effectiveness and potency. This creates logistics issues, especially in developing countries with poor infrastructure. The process of regulatory approval for biosimilars is complicated and takes time, delaying entry into market and competition. Companies have to spend a lot on R&D and clinical trials in order to satisfy safety and efficacy requirements. These supply and regulatory restrictions can reduce product availability, influence pricing strategies, and impede the timely launch of new or enhanced formulations in international markets.

Lispro Rapid Acting Insulin Market

Insulin lispro, a top rapid acting insulin analog, is commonly used for its rapid onset and consistent post-meal glucose control. It generally starts to work within 15 minutes and is favored by both Type 1 and insulin-dependent Type 2 diabetics. Lispro is commonly prescribed in basal-bolus therapy regimens and is pump-compatible. Its availability in biosimilar form has also helped see more adoption in cost-conscious markets. Global pharmaceutical giants are making improvements in lispro formulations for improved stability and convenience of use. Continuing research and growing demand for rapid-acting alternatives in both hospital and outpatient environments continue to drive market growth.

Aspart Rapid Acting Insulin Market

Insulin aspart is a widely used rapid acting insulin analog characterized by its fast absorption and onset of action. Most commonly used in combination therapy with long-acting insulins, aspart has a vital role in controlling postprandial glucose levels. Both the original and biosimilar versions of aspart are widely available, rendering it possible to be implemented across different healthcare systems. The effectiveness, safety profile, and ease of use through insulin pens and pumps all contribute to aspart being favored by endocrinologists and diabetes health care professionals. While global diabetes incidence increases, demand for aspart grows, especially in markets where healthcare access and reimbursement of analog insulins are enhancing, driving consistent market growth.

Type 2 Diabetes Rapid Acting Insulin Market

Increase in prevalence of insulin-dependent Type 2 diabetes is greatly driving demand for rapid acting insulin. As the disease progresses in severity, most patients need post-meal insulin to get good glycemic control. Rapid acting insulin assists in controlling glucose peaks and lowering HbA1c levels in these patients, frequently as part of a multiple daily injection (MDI) regimen. With the increase in obesity rates and lack of physical activity, particularly in middle-income nations, the population of Type 2 patients who are moving towards insulin therapy is on the rise. Patient education regarding the advantages of analog insulins and more expansive reimbursement practices are also accelerating the uptake of rapid acting insulin in this group.

Rapid Acting Insulin Hospital Pharmacies Market

Hospital pharmacies have an important function to play in distributing rapid acting insulin, especially in newly diagnosed cases of diabetes or patients on inpatient status. These pharmacies guarantee stock availability of crucial insulin products, such as lispro and aspart, for quick glycemic control. Within hospitals, rapid-acting insulin is typically used in surgical recovery room, emergency room, or intensive care settings in which tight control of blood sugars is required. Additionally, caregivers depend on the hospital pharmacy to have immediate availability of specialty insulin pens and vials. With hospitals increasingly dealing with diabetes as a comorbidity in the management of various conditions, the channel will likely continue to dominate its robust share in the upcoming years.

Rapid Acting Insulin Online Retailers Market

Online pharmacies and online retail websites are becoming increasingly popular for the delivery of insulin, especially among urban and tech-literate populations. These websites are convenient, priced competitively, and easily provide branded and biosimilar rapid acting insulin products. Doorstep delivery, refill reminders, and teleconsultations are a boon to patients. As the COVID-19 pandemic unfolded, online purchases of insulin gained traction, underscoring its increasing significance. With growing digital health infrastructure and improved cold chain logistics, online sales channels are likely to keep on increasing. Governments and private sector players are also investing in secure, regulated e-pharmacy platforms to provide safe distribution, further solidifying the channel's significance in the insulin ecosystem.

United States Rapid Acting Insulin Market

The U.S. is among the most significant markets for rapid acting insulin with a high prevalence of diabetes, well-developed healthcare infrastructure, and early uptake of insulin delivery technology. Gaining access with increasing availability of biosimilar insulins and price reforms is becoming better. The major players are also working on bringing ultra-rapid formulations to the market to address demand from patients for improved control of postprandial levels and convenience. The FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to NovoLog (insulin aspart), and it is the first rapid-acting insulin biosimilar in the US. Effective February 14, 2025, this approval is intended to enhance patient access to rapid-acting insulin therapy and is available in both prefilled pens and multiple-dose vials.

France Rapid Acting Insulin Market

France boasts a robust healthcare system with clearly defined reimbursement policies that facilitate access to rapid acting insulin. The market is aided by early diagnosis rates, extensive diabetes education, and uptake of insulin delivery technologies such as pumps and pens. Government support for biosimilars is enhancing affordability. Moreover, France's emphasis on innovation and clinical research guarantees a constant flow of new treatments, promoting long-term market growth.

India Rapid Acting Insulin Market

India's rapid acting insulin market is growing driven by increasing prevalence of diabetes and growing awareness regarding contemporary insulin therapy. Urban communities are more prone to opt for rapid-acting insulin, aided by enhanced access through private hospitals and web platforms. Although affordability issues persist, the emergence of biosimilars and government schemes are improving availability in urban as well as semi-urban regions. Feb 2025, Cipla has obtained regulatory clearance to launch Afrezza, the world's first ultra-rapid-acting inhaled insulin, in India, a groundbreaking development in the management of diabetes.

Saudi Arabia Rapid Acting Insulin Market

The rapid acting insulin market of Saudi Arabia is increasing progressively with growth in diabetes treatment rates and increased government investment in healthcare facilities. Public and private initiatives are directed towards increasing access to advanced insulin therapies, such as analogs like lispro and aspart. Penetration of insulin pens and digital monitoring devices is increasing treatment adherence on a large scale. Educational campaigns and subsidized pricing programs are also enhancing insulin access throughout the regions. September 2024, Biocon has collaborated with Tabuk Pharmaceuticals for the commercialization of GLP-1 products for treating diabetes and weight control in the Middle East.

Rapid Acting Insulin Market Segments

Product

1. Lispro Insulin

2. Aspart Insulin

3. Glulisine Insulin

Indication

1. Type 1 Diabetes

2. Type 2 Diabetes

Distribution Channel

1. Hospital Pharmacies

2. Drug Stores and Retail Pharmacies

3. Online Stores

Country

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. UAE

All the key players have been covered from 4 Viewpoints:

  • Overview
  • Key Persons
  • Recent Development
  • Revenue

Company Analysis

1. Alcon Inc.

2. Bausch Health Companies Inc.

3. Carl Zeiss Meditec AG

4. EssilorLuxottica SA

5. HAAG-Streit Group

6. Hoya Corporation

7. Johnson and Johnson

8. Nidek Co. Ltd

9. Topcon Corporation

10. Ziemer Ophthalmic Systems AG

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Global Rapid Acting Insulin Market

6. Market Share Analysis

  • 6.1 By Product
  • 6.2 By Indication
  • 6.3 By Distribution Channel
  • 6.4 By Countries

7. Product

  • 7.1 Lispro Insulin
  • 7.2 Aspart Insulin
  • 7.3 Glulisine Insulin

8. Indication

  • 8.1 Type 1 Diabetes
  • 8.2 Type 2 Diabetes

9. Distribution Channel

  • 9.1 Hospital Pharmacies
  • 9.2 Drug Stores and Retail Pharmacies
  • 9.3 Online Stores

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherland
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Thailand
    • 10.3.7 Malaysia
    • 10.3.8 Indonesia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 South Africa
    • 10.5.2 Saudi Arabia
    • 10.5.3 Turkey
    • 10.5.4 UAE

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 Adocia
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development & Strategies
    • 13.1.5 Revenue Analysis
  • 13.2 Biocon Limited
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development & Strategies
    • 13.2.5 Revenue Analysis
  • 13.3 Eli Lilly and Company
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development & Strategies
    • 13.3.5 Revenue Analysis
  • 13.4 Gan & Lee Pharmaceuticals Co. Ltd.
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development & Strategies
    • 13.4.5 Revenue Analysis
  • 13.5 Geropharm
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development & Strategies
    • 13.5.5 Revenue Analysis
  • 13.6 MannKind Corporation
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development & Strategies
    • 13.6.5 Revenue Analysis
  • 13.7 Merck & Co. Inc.
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development & Strategies
    • 13.7.5 Revenue Analysis
  • 13.8 Novo Nordisk A/S
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development & Strategies
    • 13.8.5 Revenue Analysis
  • 13.9 Sanofi S.A.
    • 13.9.1 Overview
    • 13.9.2 Key Persons
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Development & Strategies
    • 13.9.5 Revenue Analysis
  • 13.10 Wockhardt Ltd.
    • 13.10.1 Overview
    • 13.10.2 Key Persons
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Development & Strategies
    • 13.10.5 Revenue Analysis